Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.

CONCLUSIONS: Imatinib showed no measurable activity in patients with newly diagnosed or recurrent glioblastoma.
PMID: 31514200 [PubMed - as supplied by publisher]

Source: Oncology - September 11, 2019 Category: Cancer & Oncology Authors: Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, Schmieder K, Hochhaus A, Wenz F, Giordano FA Tags: Oncology Source Type: research